EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent Advances on Small-Molecule Antagonists Targeting TLR7

Haoyang Zheng, Peiyang Wu, Pierre-Antoine Bonnet

Molecules · 07.01.2023 · 28 (2) · 634

DOI: 10.3390/molecules28020634 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 07.01.2023. Verfasst von Haoyang Zheng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Montpellier University, 34093 Montpellier, France. Hauptthemen laut MEDLINE: Interferon Type I, Toll-Like Receptor 7. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Toll-like receptor 7 (TLR7) is a class of pattern recognition receptors (PRRs) recognizing the pathogen-associated elements and damage and as such is a major player in the innate immune system. TLR7 triggers the release of pro-inflammatory cytokines or type-I interferons (IFN), which is essential for immunoregulation. Increasing reports also highlight that the abnormal activation of endosomal TLR7 is implicated in various immune-related diseases, carcinogenesis as well as the proliferation of human immunodeficiency virus (HIV). Hence, the design and development of potent and selective TLR7 antagonists based on small molecules or oligonucleotides may offer new tools for the prevention and management of such diseases. In this review, we offer an updated overview of the main structural features and therapeutic potential of small-molecule antagonists of TLR7. Various heterocyclic scaffolds targeting TLR7 binding sites are presented: pyrazoloquinoxaline, quinazoline, purine, imidazopyridine, pyridone, benzanilide, pyrazolopyrimidine/pyridine, benzoxazole, indazole, indole, and quinoline. Additionally, their structure-activity relationships (SAR) studies associated with biological activities and protein binding modes are introduced.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interferon Type IToll-Like Receptor 7HumansCytokinesStructure-Activity Relationship

Stichwörter der Autor:innen

TLR7antagonistsheterocycleinnate immunity

Substanzen

CytokinesInterferon Type ITLR7 protein, humanToll-Like Receptor 7

Autor:innen und Institutionen

  • Faculty of Pharmacy, Montpellier University, 34093 Montpellier, France.
  • School of Life Sciences, Shanghai Normal University, Shanghai 200234, China.
  • Institut des Biomolécules Max Mousseron IBMM, Ecole Nationale Supérieure de Chimie de Montpellier ENSCM, Montpellier University, Centre National de La Recherche Scientifique CNRS, 34093 Montpellier, France.

Zitieren

APA

Zheng, H., Wu, P., & Bonnet, P. A. (2023). Recent Advances on Small-Molecule Antagonists Targeting TLR7. Molecules, 28(2), 634. https://doi.org/10.3390/molecules28020634

Vancouver

Zheng H, Wu P, Bonnet PA. Recent Advances on Small-Molecule Antagonists Targeting TLR7. Molecules. 2023;28(2):634. doi:10.3390/molecules28020634

BibTeX
@article{Zheng2023,
  author = {Zheng, Haoyang and Wu, Peiyang and Bonnet, Pierre-Antoine},
  title = {Recent Advances on Small-Molecule Antagonists Targeting TLR7},
  journal = {Molecules},
  year = {2023},
  volume = {28},
  number = {2},
  pages = {634},
  doi = {10.3390/molecules28020634}
}
Kostenlos starten →